SCHEMBL12378828

SCHEMBL12378828

CC(=O)CNc1ccc(Br)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
ALDH1A1 P00352 3/20 0.48
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPT P10636 2/20 0.48
NPC1 O15118 2/20 0.48
TSHR P16473 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 2/20 0.47
EPHX1 P07099 1/20 0.47
AGER Q15109 1/20 0.46
GRK2 P25098 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4582345 0.83 MAPT (0.54) MEN1KMT2AALDH1A1RAB9AMAPT
SCHEMBL161755 0.83 MEN1 (0.52) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL9419326 0.83 MAPT (0.54) MEN1KMT2AALDH1A1RAB9AMAPT
SCHEMBL28326343 0.82 SMN1; SMN2 (0.53) MEN1KMT2AALDH1A1RAB9ASMN1; SMN2
SCHEMBL26268944 0.82 MEN1 (0.47) MEN1KMT2AALDH1A1RAB9ASMN1; SMN2
SCHEMBL19707555 0.82 MEN1 (0.52) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL5000420 0.82 HPGD (0.57) MEN1KMT2AALDH1A1RAB9ASMN1; SMN2
Water SCHEMBL11637714 0.81 MAPT (0.52) MEN1KMT2AALDH1A1RAB9AMAPT
SCHEMBL22292620 0.81 CA1 (0.44) MEN1KMT2AALDH1A1RAB9ASMN1; SMN2
SCHEMBL9136458 0.81 RAB9A (0.48) MEN1KMT2AALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747244-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE Redx Pharma Limited (GB) 2026-05-27 EP disclosed
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2025-04-17 US disclosed
WO-2025017306-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2025-01-23 WO disclosed
EP-4466071-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) Redx Pharma Limited (GB) 2024-11-27 EP disclosed
CN-118632845-A Modulators of Rho-associated protein kinase (ROCK) 莱德克斯制药有限公司 2024-09-10 CN disclosed
WO-2023139379-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) REDX PHARMA PLC (GB) 2023-07-27 WO disclosed
US-7998961-B2 For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) SCHERING CORPORATION (US) 2011-08-16 US disclosed
US-7998961-B2 For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) SCHERING CORPORATION (US) 2011-08-16 US disclosed
US-20080226618-A1 HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS SCHERING CORPORATION 2008-09-18 US disclosed
US-20080226618-A1 HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS SCHERING CORPORATION 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080226618-A1 HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS LPXN, HAX1, LCT MEN1 1922/4885KMT2A 1628/4885ALDH1A1 1419/4885
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA MEN1 2508/4885KMT2A 2318/4885ALDH1A1 4488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.